Home Tags Cancer: Leukemia

Tag: Cancer: Leukemia

For patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma

Duvelisib Promising for Chronic Lymphocytic Leukemia, SLL

Duvelisib extended progression-free survival to 13.3 months versus 9.9 months for ofatumumab
Adolescents and young adults (aged 15 to 39 years) with acute lymphoblastic leukemia (ALL) have increased risk of on-therapy relapse and relapse after completing therapy compared with children with ALL

Risk of Relapse Up for Teens, Young Adults With Leukemia

Increased risk of on-therapy relapse, relapse after completing therapy versus children with ALL
Lumoxiti (moxetumomab pasudotox-tdfk) injection has been approved to treat certain instances of relapsed or refractory hairy cell leukemia

FDA Approves Novel Treatment for Hairy Cell Leukemia

Lumoxiti, a CD22-directed cytotoxin, approved for adults who have had at least two prior therapies
Tibsovo (ivosidenib) tablets have been approved by the U.S. Food and Drug Administration to treat relapsed or refractory acute myeloid leukemia among people with a defective IDH1 gene.

FDA Approves Tibsovo for Acute Myeloid Leukemia

Approved for adults with relapsed or refractory acute myeloid leukemia who have IDH1 mutation
Survivors of lymphoma and chronic lymphocytic leukemia have increased use of health care services versus a normative population

Lymphoma, Leukemia Survivors Have Increased Health Care Use

Survivors who are psychologically distressed use even more services than those who aren't
Underlying leukemia

Leukemia, and Its Treatment, May Pose Neurocognitive Risks

Cerebrospinal fluid biomarkers may identify those at greater risk for poor neuro-related outcomes
The detection of molecular minimal residual disease is associated with increased relapse rates in acute myeloid leukemia

Molecular Minimal Disease in Remission Predicts AML Relapse

Persistence of non-DTA mutations during remission linked to rates of relapse, survival
For patients with chronic-phase chronic myeloid leukemia

Treatment-Free Remission Feasible After Nilotinib in CML

For patients with chronic myeloid leukemia in chronic phase, TFR is feasible after second-line treatment
TP53 pathogenic variants are overrepresented in children with acute lymphoblastic leukemia and are associated with worse outcomes

TP53 Variants Linked to Childhood ALL, Poor Outcomes

Carrying germline variants linked to decreased event-free, overall survival; higher risk of second cancers
Adipocytes metabolize and inactivate the anthracycline daunorubicin

Adipocytes Metabolize, Inactivate Daunorubicin

Adipocytes metabolize daunorubicin to daunorubicinol, reducing its anti-leukemia effect